![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SNRNP40 |
Gene summary for SNRNP40 |
![]() |
Gene information | Species | Human | Gene symbol | SNRNP40 | Gene ID | 9410 |
Gene name | small nuclear ribonucleoprotein U5 subunit 40 | |
Gene Alias | 40K | |
Cytomap | 1p35.2 | |
Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | A0MNP2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9410 | SNRNP40 | C38 | Human | Oral cavity | OSCC | 1.09e-05 | 1.04e+00 | 0.172 |
9410 | SNRNP40 | C43 | Human | Oral cavity | OSCC | 1.24e-41 | 8.56e-01 | 0.1704 |
9410 | SNRNP40 | C46 | Human | Oral cavity | OSCC | 3.54e-31 | 8.46e-01 | 0.1673 |
9410 | SNRNP40 | C51 | Human | Oral cavity | OSCC | 3.02e-10 | 8.44e-01 | 0.2674 |
9410 | SNRNP40 | C57 | Human | Oral cavity | OSCC | 2.22e-04 | 5.35e-01 | 0.1679 |
9410 | SNRNP40 | C06 | Human | Oral cavity | OSCC | 5.87e-05 | 1.33e+00 | 0.2699 |
9410 | SNRNP40 | C08 | Human | Oral cavity | OSCC | 2.56e-25 | 6.90e-01 | 0.1919 |
9410 | SNRNP40 | C09 | Human | Oral cavity | OSCC | 1.13e-05 | 2.51e-01 | 0.1431 |
9410 | SNRNP40 | LN22 | Human | Oral cavity | OSCC | 1.70e-06 | 1.08e+00 | 0.1733 |
9410 | SNRNP40 | LN46 | Human | Oral cavity | OSCC | 5.88e-16 | 9.38e-01 | 0.1666 |
9410 | SNRNP40 | LP15 | Human | Oral cavity | LP | 2.78e-02 | 1.05e+00 | 0.2174 |
9410 | SNRNP40 | LP17 | Human | Oral cavity | LP | 2.36e-06 | 1.04e+00 | 0.2349 |
9410 | SNRNP40 | SYSMH2 | Human | Oral cavity | OSCC | 1.84e-12 | 6.32e-01 | 0.2326 |
9410 | SNRNP40 | SYSMH3 | Human | Oral cavity | OSCC | 1.32e-29 | 1.01e+00 | 0.2442 |
9410 | SNRNP40 | SYSMH6 | Human | Oral cavity | OSCC | 1.24e-03 | 2.85e-01 | 0.1275 |
9410 | SNRNP40 | P1_cSCC | Human | Skin | cSCC | 1.35e-15 | 7.42e-01 | 0.0292 |
9410 | SNRNP40 | P2_cSCC | Human | Skin | cSCC | 3.11e-09 | 5.16e-01 | -0.024 |
9410 | SNRNP40 | P4_cSCC | Human | Skin | cSCC | 7.52e-22 | 7.60e-01 | -0.00290000000000005 |
9410 | SNRNP40 | P10_cSCC | Human | Skin | cSCC | 5.03e-35 | 1.16e+00 | 0.1017 |
9410 | SNRNP40 | male-WTA | Human | Thyroid | PTC | 6.52e-05 | 4.32e-02 | 0.1037 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
GO:000037512 | Liver | Cirrhotic | RNA splicing, via transesterification reactions | 175/4634 | 324/18723 | 5.95e-30 | 7.47e-27 | 175 |
GO:000037712 | Liver | Cirrhotic | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
GO:000039812 | Liver | Cirrhotic | mRNA splicing, via spliceosome | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
GO:000037522 | Liver | HCC | RNA splicing, via transesterification reactions | 228/7958 | 324/18723 | 1.47e-24 | 4.06e-22 | 228 |
GO:000037722 | Liver | HCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
GO:000039822 | Liver | HCC | mRNA splicing, via spliceosome | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
GO:000037519 | Oral cavity | OSCC | RNA splicing, via transesterification reactions | 225/7305 | 324/18723 | 5.20e-29 | 2.99e-26 | 225 |
GO:000037719 | Oral cavity | OSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
GO:000039819 | Oral cavity | OSCC | mRNA splicing, via spliceosome | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
GO:0008380110 | Oral cavity | LP | RNA splicing | 237/4623 | 434/18723 | 1.82e-41 | 3.79e-38 | 237 |
GO:0000375110 | Oral cavity | LP | RNA splicing, via transesterification reactions | 181/4623 | 324/18723 | 1.36e-33 | 1.70e-30 | 181 |
GO:0000377110 | Oral cavity | LP | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
GO:0000398110 | Oral cavity | LP | mRNA splicing, via spliceosome | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
hsa0304016 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
hsa0304026 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
hsa0304036 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SNRNP40 | SNV | Missense_Mutation | c.125N>A | p.Gly42Glu | p.G42E | Q96DI7 | protein_coding | tolerated(0.18) | benign(0.026) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SNRNP40 | SNV | Missense_Mutation | c.68A>T | p.Glu23Val | p.E23V | Q96DI7 | protein_coding | deleterious(0) | benign(0.261) | TCGA-EW-A1OV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | SD | |
SNRNP40 | SNV | Missense_Mutation | c.67G>C | p.Glu23Gln | p.E23Q | Q96DI7 | protein_coding | tolerated(0.13) | benign(0.134) | TCGA-EW-A1OV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | SD | |
SNRNP40 | SNV | Missense_Mutation | novel | c.152N>T | p.Arg51Ile | p.R51I | Q96DI7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
SNRNP40 | SNV | Missense_Mutation | c.517N>A | p.Asp173Asn | p.D173N | Q96DI7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
SNRNP40 | SNV | Missense_Mutation | c.629N>A | p.Ser210Tyr | p.S210Y | Q96DI7 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SNRNP40 | SNV | Missense_Mutation | novel | c.1061G>C | p.Gly354Ala | p.G354A | Q96DI7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A2IO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
SNRNP40 | SNV | Missense_Mutation | c.628T>G | p.Ser210Ala | p.S210A | Q96DI7 | protein_coding | tolerated(0.16) | possibly_damaging(0.758) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SNRNP40 | SNV | Missense_Mutation | novel | c.825N>T | p.Lys275Asn | p.K275N | Q96DI7 | protein_coding | deleterious(0.02) | benign(0.274) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SNRNP40 | SNV | Missense_Mutation | rs36013190 | c.389N>G | p.Asp130Gly | p.D130G | Q96DI7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |